We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alkermes' Schizophrenia Drug Gets Favorable FDA Panel Vote
Read MoreHide Full Article
Alkermes plc (ALKS - Free Report) announced that it received positive votes for ALKS 3831 from the joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, appointed by the FDA. Shares of the company increased 13.2% following the news in pre-market. However, shares of the company have decreased 17.4% year to date against the industry’s growth of 1.8%.
ALKS 3831 (olanzapine/samidorphan) is an investigational, novel, once-daily, oral atypical antipsychotic drug candidate being evaluated for the treatment of adults with schizophrenia and bipolar I disorder. Schizophrenia is a chronic, severe and disabling brain disorder. Bipolar disorder is a brain disorder that causes unusual shifts in a person's mood, energy and ability to function.
During the joint meeting, the group voted that the samidorphan meaningfully mitigates olanzapine-associated weight gain with a 16-1 vote. The committee also ruled the safety profile of ALKS 3831, which has been adequately characterized with a 13-3 vote.The committees jointly voted that labeling is sufficient to mitigate the risks related to the opioid antagonist action of samidorphan in an 11-6 vote.
Though the FDA is not bound by it, the joint advisory committee's recommendationswill be considered by the agencyin its review of the new drug application (NDA) for ALKS 3831.The action date for the ALKS 3831 NDA is Nov 15, 2020. The NDA is supported by data from 18 studies evaluating ALKS 3831 and nine studies evaluating samidorphan alone.
Other drugsin the schizophrenia treatment market include AstraZeneca plc's (AZN - Free Report) Seroquel XR, Johnson & Johnson's (JNJ - Free Report) Risperdal Consta and AbbVie’s (ABBV - Free Report) Vraylar. Vraylar is also approved for the treatment of adults with major depressive episodes related to bipolar I disorder.
In addition to the companies you learned about above, we invite you to learn more about profiting from the upcoming presidential election. Trillions of dollars will shift into new market sectors after the votes are tallied, and investors could see significant gains. This report reveals specific stocks that could soar: 6 if Trump wins, 6 if Biden wins.
Image: Bigstock
Alkermes' Schizophrenia Drug Gets Favorable FDA Panel Vote
Alkermes plc (ALKS - Free Report) announced that it received positive votes for ALKS 3831 from the joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, appointed by the FDA. Shares of the company increased 13.2% following the news in pre-market. However, shares of the company have decreased 17.4% year to date against the industry’s growth of 1.8%.
ALKS 3831 (olanzapine/samidorphan) is an investigational, novel, once-daily, oral atypical antipsychotic drug candidate being evaluated for the treatment of adults with schizophrenia and bipolar I disorder. Schizophrenia is a chronic, severe and disabling brain disorder. Bipolar disorder is a brain disorder that causes unusual shifts in a person's mood, energy and ability to function.
During the joint meeting, the group voted that the samidorphan meaningfully mitigates olanzapine-associated weight gain with a 16-1 vote. The committee also ruled the safety profile of ALKS 3831, which has been adequately characterized with a 13-3 vote.The committees jointly voted that labeling is sufficient to mitigate the risks related to the opioid antagonist action of samidorphan in an 11-6 vote.
Though the FDA is not bound by it, the joint advisory committee's recommendationswill be considered by the agencyin its review of the new drug application (NDA) for ALKS 3831.The action date for the ALKS 3831 NDA is Nov 15, 2020. The NDA is supported by data from 18 studies evaluating ALKS 3831 and nine studies evaluating samidorphan alone.
Other drugsin the schizophrenia treatment market include AstraZeneca plc's (AZN - Free Report) Seroquel XR, Johnson & Johnson's (JNJ - Free Report) Risperdal Consta and AbbVie’s (ABBV - Free Report) Vraylar. Vraylar is also approved for the treatment of adults with major depressive episodes related to bipolar I disorder.
Alkermes currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Alkermes plc Price
Alkermes plc price | Alkermes plc Quote
Zacks’ 2020 Election Stock Report:
In addition to the companies you learned about above, we invite you to learn more about profiting from the upcoming presidential election. Trillions of dollars will shift into new market sectors after the votes are tallied, and investors could see significant gains. This report reveals specific stocks that could soar: 6 if Trump wins, 6 if Biden wins.
Check out the 2020 Election Stock Report >>